Literature DB >> 18349369

Invasive pneumococcal disease: epidemiology in children and adults prior to implementation of the conjugate vaccine in the Oxfordshire region, England.

Dona Foster1,2, Kyle Knox3, A S Walker4, D T Griffiths2, Hazel Moore2, Elizabeth Haworth1, Timothy Peto4, Angela B Brueggemann5, Derrick W Crook2.   

Abstract

A 10-year invasive pneumococcal disease (IPD) enhanced surveillance project in the Oxfordshire region of the UK between 1996 and 2005 identified a total of 2691 Streptococcus pneumoniae isolates from all ages that provided a comprehensive description of pneumococcal epidemiology. All isolates were serotyped and those from children under 5 years of age were genotyped and a matched case-control study using adults hospitalized between 1995 and 2000 was performed to estimate the effectiveness of the pneumococcal polysaccharide vaccine in the local population. Fifty-one serotypes were isolated, with different age distributions. The overall incidence of IPD was 9.2 cases per 100 000 population per annum [95 % confidence interval (CI), 8.6-9.9] and that of meningitis was 0.7 per 100 000 population per annum (95 % CI 0.5-0.9). After adjusting for age, serotype 1 was found to be less likely to be associated with meningitis versus other IPD, compared with the most common serotype 14, whereas serotype 12F was more likely to cause meningitis than other IPD. There were significant temporal changes in IPD incidence of four serotypes, with decreases in serotypes 1, 12F and 14 and increases in serotype 8. A possible novel variant (from serotype 6A to 6B) was found using multilocus sequence typing analysis. From the matched case-control study of adults, the pneumococcal polysaccharide vaccine effectiveness was estimated to be 43 % (2-68 %), which did not change significantly after adjustment for pre-existing co-morbidities. The data provide a baseline against which the impact of the pneumococcal conjugate vaccine introduced in the UK in 2006 could be measured.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18349369     DOI: 10.1099/jmm.0.47690-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  11 in total

1.  Characterization of gene use and efficacy of mouse monoclonal antibodies to Streptococcus pneumoniae serotype 8.

Authors:  Masahide Yano; Liise-anne Pirofski
Journal:  Clin Vaccine Immunol       Date:  2010-11-10

2.  Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands.

Authors:  Gerwin D Rodenburg; Sabine C de Greeff; Angelique G C S Jansen; Hester E de Melker; Leo M Schouls; Eelko Hak; Lodewijk Spanjaard; Elisabeth A M Sanders; Arie van der Ende
Journal:  Emerg Infect Dis       Date:  2010-05       Impact factor: 6.883

3.  Temporal Variations among Invasive Pneumococcal Disease Serotypes in Children and Adults in Germany (1992-2008).

Authors:  Matthias Imöhl; Ralf René Reinert; Mark van der Linden
Journal:  Int J Microbiol       Date:  2010-06-30

4.  Age-associated inflammation and toll-like receptor dysfunction prime the lungs for pneumococcal pneumonia.

Authors:  Ernesto Hinojosa; Angela R Boyd; Carlos J Orihuela
Journal:  J Infect Dis       Date:  2009-08-15       Impact factor: 5.226

Review 5.  Pneumococcal vaccination during pregnancy for preventing infant infection.

Authors:  Surasith Chaithongwongwatthana; Waralak Yamasmit; Sompop Limpongsanurak; Pisake Lumbiganon; Jorge E Tolosa
Journal:  Cochrane Database Syst Rev       Date:  2015-01-23

6.  Minimum incidence of adult invasive pneumococcal disease in Blantyre, Malawi an urban african setting: a hospital based prospective cohort study.

Authors:  Naor Bar-Zeev; Neema Mtunthama; Stephen B Gordon; Gershom Mwafulirwa; Neil French
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

Review 7.  A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults.

Authors:  James D Chalmers; James Campling; Alison Dicker; Mark Woodhead; Harish Madhava
Journal:  BMC Pulm Med       Date:  2016-05-11       Impact factor: 3.317

8.  Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England.

Authors:  Jo Southern; Nick Andrews; Pamela Sandu; Carmen L Sheppard; Pauline A Waight; Norman K Fry; Albert Jan Van Hoek; Elizabeth Miller
Journal:  PLoS One       Date:  2018-05-25       Impact factor: 3.240

9.  Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study.

Authors:  Stephanie W Lo; Rebecca A Gladstone; Andries J van Tonder; John A Lees; Mignon du Plessis; Rachel Benisty; Noga Givon-Lavi; Paulina A Hawkins; Jennifer E Cornick; Brenda Kwambana-Adams; Pierra Y Law; Pak Leung Ho; Martin Antonio; Dean B Everett; Ron Dagan; Anne von Gottberg; Keith P Klugman; Lesley McGee; Robert F Breiman; Stephen D Bentley
Journal:  Lancet Infect Dis       Date:  2019-06-10       Impact factor: 71.421

10.  Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis.

Authors:  Sarah Pugh; Matt Wasserman; Margaret Moffatt; Susana Marques; Juan Manuel Reyes; Victor A Prieto; Davy Reijnders; Mark H Rozenbaum; Juha Laine; Heidi Åhman; Raymond Farkouh
Journal:  Infect Dis Ther       Date:  2020-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.